Health authorities in the Democratic Republic of Congo are deploying Merck's vaccine and Gilead's antiviral drugs as the Ebola outbreak continues to worsen.
The World Health Organization reports that the current strain may be mutating, necessitating urgent clinical trials for new treatments to contain the spread.
Moderna has also initiated Phase 1 human trials for a new Bundibugyo Ebola vaccine, which has received approval for testing in Canada and other regions.